@TheSpaniard Equity markets and investment are meant to be all about forward earnings and expectations. But you are right. Until investors get actual confirmation of revenue growth, etc, even though the writing is on the wall (in massive letters) OCC shareholders will continue to sell down enough in volume to restrain any ascent the forward earnings prospects (that are now far more immediate) really warrants.
In that vein here is confirmation, AFTER the fact, actual confirmation, for OCC investors.
Striate is already available for purchase in the US on Bio Horizons website:
https://usstore.biohorizons.com/striate
The long awaited commercialisation of OCC's products is already here, in US markets as we type, not just rhetoric, actually commercially available with a top five US dental Pharma, endorsed under their company name:
@TheSpaniard Equity markets and investment are meant to be all...
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.0¢ |
Change
0.010(2.63%) |
Mkt cap ! $81.63M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 39.0¢ | 37.5¢ | $49.66K | 129.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 20305 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 77938 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| OCC (ASX) Chart |